Therapeutic Targets Database
BIDD Pharmainformatics Databases


TTD Target ID: TTDC00193

Target Information
NameNeuropeptide Y receptor type 1    
Type of targetClinical trial target    
Neuropeptide Y Y(1) receptor    
Neuropeptide Y receptor Y1    
Neuropeptide Y-Y1 receptor    
[ICD9: 338   ICD10: R52]
Anxiety disorder, unspecified
[ICD9: 300   ICD10: F40-F42]
Cardiovascular disease, unspecified
[ICD9: 390-459   ICD10: I00-I99]
[ICD9: 780.3   ICD10: R56.0]
Drug dependence
[ICD9: 303-304   ICD10: F10.2-F19.2]
Metabolic disorder, unspecified
[ICD9: 270-279   ICD10: E70-E89]
[ICD9: 278   ICD10: E66]
Pain, unspecified
[ICD9: 338,780   ICD10: R52, G89]
[ICD9: 472.0, 477   ICD10: J00, J30, J31.0]
Drug(s)Benzylamine derivativePhase IEating disorder (bulimia) Obesity Hypertension Congestive heart failure[3]
PD-160170PreclinicalHypertension. Obesity, Heart disease[4]
BioChemical ClassG-protein coupled receptor (rhodopsin family)    
PathwayNeuroactive ligand-receptor interaction
UniProt IDP25929
PDB Structure2F1U; 2IIL.    
FunctionReceptor for neuropeptide y and peptide yy. The rank order of affinity of this receptor for pancreatic polypeptides is npy > [pro-34] pyy, pyy and [leu-31, pro-34] npy > npy (2-36) > [ile-31, gln-34] pp and pyy (3-36) > pp > npy free acid.    
Target ValidationClick to Find Target Validation Information.    
Inhibitor4- (4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one[5]
AcPYY (22-36)[6]
N-arylpiperazine derivative[9]
N-arylpiperazine derivative[9]
N-arylpiperazine derivative[9]
N-arylpiperazine derivative[9]
N-arylpiperazine derivative[9]
N-arylpiperazine derivative[9]
N-arylpiperazine derivative[9]
N-arylpiperazine derivative[9]
N-arylpiperazine derivative[9]
N-arylpiperazine derivative[9]
PYY (22-36)[6]
PYY (3-36)[6]
neuropeptide Y[13]
BIBP 3226[15][16]
Benzylamine derivative[3]
NPY-1 antagonist[3]
SR 120819A[19]
Cross References 3D Structure
Related Literature
On-Line Medical Dictionary
Ref 1Neuropeptide Y and its receptors as potential therapeutic drug targets. Clin Chim Acta. 2002 Dec;326(1-2):3-25. To Reference
Ref 2Neuropeptide Y receptors as targets for anti-obesity drug development: perspective and current status. Eur J Pharmacol. 2002 Apr 12;440(2-3):173-87. To Reference
Ref 3Emerging drugs for eating disorder treatment. Expert Opin Emerg Drugs. 2006 May;11(2):315-36. To Reference
Ref 4Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. To Reference
Ref 5J Med Chem. 2010 Sep 9;53(17):6386-97.Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 receptor agonist with unprecedented selectivity and procognitive potential. To Reference
Ref 6Bioorg Med Chem Lett. 2007 Jan 15;17(2):538-41. Epub 2006 Oct 7.Identification of selective neuropeptide Y2 peptide agonists. To Reference
Ref 7J Med Chem. 2006 Apr 20;49(8):2661-5.Neuropeptide Y (NPY) Y4 receptor selective agonists based on NPY(32-36): development of an anorectic Y4 receptor selective agonist with picomolar affinity. To Reference
Ref 8Bioorg Med Chem. 2010 Sep 1;18(17):6292-304. Epub 2010 Jul 16.N(G)-Acyl-argininamides as NPY Y(1) receptor antagonists: Influence of structurally diverse acyl substituents on stability and affinity. To Reference
Ref 9Bioorg Med Chem Lett. 2004 Dec 20;14(24):5975-8.Isosteric N-arylpiperazine replacements in a series of dihydropyridine NPY1 receptor antagonists. To Reference
Ref 10Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. Epub 2010 Oct 21.In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). To Reference
Ref 11Bioorg Med Chem Lett. 2007 Apr 1;17(7):1916-9. Epub 2007 Jan 24.A long-acting selective neuropeptide Y2 receptor PEGylated peptide agonist reduces food intake in mice. To Reference
Ref 12J Med Chem. 2008 Dec 25;51(24):8168-72.Guanidine-acylguanidine bioisosteric approach in the design of radioligands: synthesis of a tritium-labeled N(G)-propionylargininamide ([3H]-UR-MK114) as a highly potent and selective neuropeptide Y Y1 receptor antagonist. To Reference
Ref 13J Nat Prod. 2009 Dec;72(12):2172-6.5-OHKF and NorKA, depsipeptides from a Hawaiian collection of Bryopsis pennata: binding properties for NorKA to the human neuropeptide Y Y1 receptor. To Reference
Ref 14Neuropeptide Y induced modulation of dopamine synthesis in the striatum. Regul Pept. 2005 Jul 15;129(1-3):73-8. To Reference
Ref 15Effects of a selective neuropeptide Y Y(1) receptor antagonist BIBP 3226 on double peaked vasoconstrictor responses to periarterial nerve stimulation in canine splenic arteries. Br J Pharmacol. 2000 Aug;130(7):1699-705. To Reference
Ref 16Intracerebroventricular injection of a neuropeptide Y-Y1 receptor agonist increases while BIBP3226, a Y1 antagonist, reduces the infarct volume following transient middle cerebral artery occlusion in rats. Neuroscience. 2003;116(1):119-26. To Reference
Ref 17Dihydropyridine neuropeptide Y Y(1) receptor antagonists. Bioorg Med Chem Lett. 2002 Feb 11;12(3):379-82. To Reference
Ref 18The novel neuropeptide Y Y(1) receptor antagonist J-104870: a potent feeding suppressant with oral bioavailability. Biochem Biophys Res Commun. 1999 Dec 9;266(1):88-91. To Reference
Ref 19SR 120819A, an orally-active and selective neuropeptide Y Y1 receptor antagonist. FEBS Lett. 1995 Apr 3;362(2):192-6. To Reference


Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.

Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore

All rights reserved.

Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links


Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543